84th European Atherosclerosis Society Congress 2016
PCSK9 inhibitors in the clinic: New analyses provide clarification on long-term treatment issues
Reports from EAS Congress provide important insights into the long-term use of PCSK9 inhibitors. Statins are the first-line therapy for LDL cholesterol lowering given indisputable evidence that this treatment reduces cardiovascular events in both men and women (1,2). The PCSK9 inhibitors undoubtedly have proven efficacy,…
read more »
EAS Congress Innsbruck: Mixed results with novel agents in homozygous FH
The Clinical Late breaker session reported on three agents with potential for the management of homozygous familial hypercholesterolaemia (FH, inherited high cholesterol). One of these – evinacumab (REGN1500), a human monoclonal antibody to angiopoietin-like protein 3 (ANGPTL3) – showed interesting results in a small proof-of-concept study…
read more »
Is lipoprotein(a) a cause of clinical familial hypercholesterolaemia?
Familial hypercholesterolaemia (FH, inherited high cholesterol) is a common autosomal dominant condition which is characterized by raised LDL cholesterol, family history of dyslipidaemia, and early onset of coronary heart disease. Beyond mutations in the LDLR, APOB and PCSK9 genes, a new study from the University…
read more »
Low LDL-C, PCSK9 and dementia risk?
An ongoing debate among the experts is whether the very low levels of LDL cholesterol with PCSK9 inhibitor treatment might be associated with neurocognitive events. In fact, the debate predates the PCSK9 inhibitors, with statins linked with cognitive impairment (1-4). However, when the statin data…
read more »
TAUSSIG: Does adding evolocumab reduce cardiovascular events in homozygous FH?
84th European Atherosclerosis Society Congress, 29 May- 1 June, Innsbruck, Austria Patients with homozygous familial hypercholesterolaemia (FH, inherited high cholesterol) are at extremely high risk of premature cardiovascular events due to the burden of elevated LDL cholesterol. Indeed, cardiovascular death at an early age is…
read more »
Changing the message on LDL cholesterol: Lifetime exposure is key
84th European Atherosclerosis Society Congress, 29 May – 1 June, Innsbruck, Austria Until recently, the emphasis in clinical care has been to lower LDL cholesterol to the recommended goal, or even below these limits, as investigated with the PCSK9 inhibitors. However, in his Key Note…
read more »
